1. |
Cutts FT, Franceschi S, Goldie S,et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ, 2007, 85(9): 719-726.
|
2. |
Lu W, Duan X, Cen Y. Overview in Epidemiology on Cervical Cancer. Inner Mongolia Med, 2007, 39(8): 967-970.
|
3. |
Sanjose SD, Quint WG, Alemany L,et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol, 2010, 11(11): 1048-1056.
|
4. |
Zhu FC, Chen W, Hu YM,et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: results from a randomized controlled trial. Int J Cancer, 2014, 135(11): 2612-2622.
|
5. |
人乳头瘤病毒预防性疫苗临床试验有效性评估专家组. 有关人乳头瘤病毒预防性疫苗临床试验有效性评估的专家共识. 中华肿瘤杂志, 2013, 35(7): 552-554.
|
6. |
Levin CE, Sellors J, Shi JF,et al. Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer, 2010, 127(6): 1404-1411.
|
7. |
唐晓, 乔友林, 李国荣, 等. Markov 模型在DALY 计算中的应用. 中国卫生统计, 2012, 29(2): 296-298.
|
8. |
Simonella L, Howard K, Canfell K. A survey of population-based utility scores for cervical cancer prevention. BMC Res Notes, 2014, 7(1): 899.
|
9. |
慈璞娲, 赵方辉, 王临虹, 等. 宫颈上皮内瘤变自然史转移概率的研究. 中国肿瘤, 2011, 20(9): 694-698.
|
10. |
陈蕊. 利用 Markov 模型对宫颈癌筛查方案的卫生经济学评价研究与应用. 华南理工大学, 2015.
|